Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, PK and PD of EV-077-3201-2TBS in healthy and type 2 diabetic subjects
2011-003808-20Phase 2Terminated
- Sponsor
- Evolva
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of EV-077 in type 2 diabetes mellitus (T2DM), sponsored by Evolva. Primary endpoint: Safety and tolerability of multiple doses of EV-077-3201-2TBS over 4 weeks in healthy subjects (Part A). Started Aug 2011; status: terminated.
02
Drugs
EV-077
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-003808-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003808-20.